- Home
- HYPR vs SER Comparison
HYPR vs SER Comparison
Compare HYPR & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYPR | SER |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.0M | 42.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | HYPR | SER |
|---|---|---|
| Price | $1.07 | $3.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $1.28 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 614.7K | 17.2K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,591,000.00 | $116,000.00 |
| Revenue This Year | $5.17 | $134.46 |
| Revenue Next Year | $35.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.53 | $3.28 |
| 52 Week High | $2.22 | $7.92 |
Technical Indicators
Market Signals| Indicator | HYPR | SER |
|---|---|---|
| Relative Strength Index (RSI) | 48.74 | 30.89 |
| Support Level | $0.85 | $3.68 |
| Resistance Level | $1.18 | $4.26 |
| Average True Range (ATR) | 0.09 | 0.26 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 68.37 | 1.94 |
Price Performance
Historical ComparisonAbout HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.